Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

SORIATANE 10 MG

ACITRETIN : 10 MG · DIN 02070847 · ALLERGAN INC

Health Canada status: MARKETED

What is SORIATANE?

SORIATANE 10 MG contains ACITRETIN : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02070847, held by ALLERGAN INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 07-Dec-2019. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is SORIATANE used for?

SORIATANE (acitretin) is indicated for severe psoriasis (includes erythrodermic and pustular types) and other disorders of keratinization. Severe psoriasis involves more than 10% of body surface area or is physically, occupationally or psychologically disabling. SORIATANE should be reserved for patients unresponsive to or intolerant of standard treatment due to significant adverse effects.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02070847
Brand nameSORIATANE
Generic / active ingredientACITRETIN : 10 MG
ManufacturerALLERGAN INC
Strength10 MG
Dosage formCAPSULE
Route of administrationORAL
SchedulePrescription
ATC codeD05BB02 ACITRETIN
BiosimilarNo
Health Canada statusMARKETED
Status date07-Dec-2019

How is it administered?

Initial: 25 mg/day with main meal. May increase to max 75 mg/day after 4 weeks if needed. Maintenance: 25-50 mg/day for psoriasis; 10-50 mg/day for keratinization disorders.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

null

How is it supplied?

units of 30 capsules contained in a "push-through blister" package

Contraindications

Pregnancy; females of childbearing potential (unless strict contraception used); breastfeeding; severe hepatic/renal impairment; chronic hyperlipidemia; use with tetracyclines, methotrexate, or Vit A.

Warnings and precautions

Serious risk of birth defects; hepatotoxicity (monitor LFTs); pseudotumor cerebri; psychiatric effects (depression, suicidality); hypertriglyceridemia (pancreatitis risk); decreased night vision.

What can be used instead?

Other Canadian products sharing ATC code D05BB02 ACITRETIN. 6 of 7 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
MINT-ACITRETIN10 MGCAPSULEMINT PHARMACEUTICALS INCMARKETEDDIN 02468840
MINT-ACITRETIN25 MGCAPSULEMINT PHARMACEUTICALS INCMARKETEDDIN 02468859
SORIATANE25 MGCAPSULEALLERGAN INCMARKETEDDIN 02070863
TARO-ACITRETIN10 MGCAPSULETARO PHARMACEUTICALS INCMARKETEDDIN 02466074
TARO-ACITRETIN25 MGCAPSULETARO PHARMACEUTICALS INCMARKETEDDIN 02466082
JAMP ACITRETIN25 MGCAPSULEJAMP PHARMA CORPORATIONAPPROVEDDIN 02540703

Who else supplies ACITRETIN worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. ACITRETIN appears in 38 registered pack listings across 10 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for SORIATANE

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for SORIATANE

Health Canada Drug Product Database (DPD), DIN 02070847. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.